MX2009007777A - Terapia de combinacion que comprende romidepsina y bortezomib. - Google Patents
Terapia de combinacion que comprende romidepsina y bortezomib.Info
- Publication number
- MX2009007777A MX2009007777A MX2009007777A MX2009007777A MX2009007777A MX 2009007777 A MX2009007777 A MX 2009007777A MX 2009007777 A MX2009007777 A MX 2009007777A MX 2009007777 A MX2009007777 A MX 2009007777A MX 2009007777 A MX2009007777 A MX 2009007777A
- Authority
- MX
- Mexico
- Prior art keywords
- romidepsin
- bortezomib
- proteasome inhibitor
- combination therapy
- cells
- Prior art date
Links
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 title abstract 4
- 229960003452 romidepsin Drugs 0.000 title abstract 4
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 title abstract 4
- 108010091666 romidepsin Proteins 0.000 title abstract 4
- 229960001467 bortezomib Drugs 0.000 title abstract 3
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 229940079156 Proteasome inhibitor Drugs 0.000 abstract 3
- 230000003211 malignant effect Effects 0.000 abstract 3
- 239000003207 proteasome inhibitor Substances 0.000 abstract 3
- 208000016691 refractory malignant neoplasm Diseases 0.000 abstract 2
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002489 hematologic effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención proporciona una terapia de combinación para tratar cáncer y otros neoplasmas incluyendo romidepsina y un inhibidor de proteasomas. Cuando se administran juntos, la romidepsina y un inhibidor de proteasomas (por ejemplo, bortezomib) interactúan sinérgicamente para matar selectivamente células malignas a bajas (nanomolares) concentraciones. El efecto es particularmente pronunciado en células hematológicas malignas (por ejemplo, leucemia, linfoma, mieloma múltiple). La combinación también se ha encontrado útil para tratar cánceres resistentes a bortezomib y cánceres resistentes a esteroides. La invención proporciona métodos para matar células malignas in vitro e in vivo. Se proporcionan también composiciones farmacéuticas, preparaciones y kits que incluyen romidepsina y un inhibidor de proteasomas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88616907P | 2007-01-23 | 2007-01-23 | |
| US577407P | 2007-12-07 | 2007-12-07 | |
| PCT/US2008/000850 WO2008091620A2 (en) | 2007-01-23 | 2008-01-23 | Combination therapy comprising romidepsin and i.a. bortezomib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009007777A true MX2009007777A (es) | 2009-12-16 |
Family
ID=39323892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009007777A MX2009007777A (es) | 2007-01-23 | 2008-01-23 | Terapia de combinacion que comprende romidepsina y bortezomib. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20090105200A1 (es) |
| EP (1) | EP2117556A2 (es) |
| JP (1) | JP2010516767A (es) |
| AU (1) | AU2008209555A1 (es) |
| CA (1) | CA2676387A1 (es) |
| IL (1) | IL199992A0 (es) |
| MX (1) | MX2009007777A (es) |
| WO (1) | WO2008091620A2 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2623113B1 (en) | 2005-11-09 | 2017-05-31 | Onyx Therapeutics, Inc. | Compound for enzyme inhibition |
| NZ597545A (en) | 2006-06-19 | 2013-07-26 | Proteolix Inc | Peptide epoxyketones for proteasome inhibition |
| EP2102230A2 (en) * | 2006-12-29 | 2009-09-23 | Gloucester Pharmaceuticals, Inc. | Purifiction of romidepsin |
| CN103497238A (zh) * | 2006-12-29 | 2014-01-08 | 细胞基因公司 | 制备Romidepsin |
| CA2701778C (en) | 2007-10-04 | 2018-09-11 | Onyx Therapeutics, Inc. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
| JP5675629B2 (ja) * | 2008-10-21 | 2015-02-25 | オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ペプチドエポキシケトンを用いた併用療法 |
| KR20170060179A (ko) | 2008-11-13 | 2017-05-31 | 길리아드 칼리스토가 엘엘씨 | 혈액 종양에 대한 요법 |
| US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
| AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
| WO2010106135A1 (en) | 2009-03-20 | 2010-09-23 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Combined use for the treatment of ovarian carcinoma |
| AU2009347159B2 (en) * | 2009-05-27 | 2015-09-03 | Cephalon, Inc. | Combination therapy for the treatment of multiple myeloma |
| WO2011060179A1 (en) | 2009-11-13 | 2011-05-19 | Onyx Therapeutics, Inc | Use of peptide epoxyketones for metastasis suppression |
| AU2011223795B2 (en) | 2010-03-01 | 2015-11-05 | Onyx Therapeutics, Inc. | Compounds for immunoproteasome inhibition |
| CN102946879B (zh) * | 2010-04-19 | 2015-04-22 | 尼基制药公司 | 一种蛋白酶体抑制剂和镓络合物在制备治疗增殖性疾病的药物中的应用 |
| WO2014011695A2 (en) | 2012-07-09 | 2014-01-16 | Onyx Therapeutics, Inc. | Prodrugs of peptide epoxy ketone protease inhibitors |
| RU2018114459A (ru) * | 2015-09-21 | 2019-10-23 | Ифом Фондационе Иституто Фирк Ди Онколоджа Молеколаре | Новые стратегии лечения рака крови |
| WO2017091762A1 (en) | 2015-11-25 | 2017-06-01 | Io Therapeutics, Inc. | Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer |
| CN119698276A (zh) * | 2022-06-07 | 2025-03-25 | 蓝腾制药公司 | 用酰基富烯与依鲁替尼或硼替佐米的组合治疗癌症 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1638541B1 (en) * | 2003-06-27 | 2010-05-19 | Astellas Pharma Inc. | Therapeutic agent for soft tissue sarcoma |
| WO2007146234A2 (en) * | 2006-06-09 | 2007-12-21 | Merrion Research Ii Limited | Solid oral dosage form containing an enhancer |
| US20090270419A1 (en) * | 2006-09-15 | 2009-10-29 | Janine Arts | Combinations of class-i specific histone deacetylase inhibitors with proteasome inhibitors |
| WO2009067453A1 (en) * | 2007-11-19 | 2009-05-28 | Syndax Pharmaceuticals, Inc. | Combinations of hdac inhibitors and proteasome inhibitors |
-
2008
- 2008-01-23 MX MX2009007777A patent/MX2009007777A/es not_active Application Discontinuation
- 2008-01-23 EP EP08713230A patent/EP2117556A2/en not_active Withdrawn
- 2008-01-23 CA CA002676387A patent/CA2676387A1/en not_active Abandoned
- 2008-01-23 US US12/009,867 patent/US20090105200A1/en not_active Abandoned
- 2008-01-23 AU AU2008209555A patent/AU2008209555A1/en not_active Abandoned
- 2008-01-23 WO PCT/US2008/000850 patent/WO2008091620A2/en not_active Ceased
- 2008-01-23 JP JP2009547278A patent/JP2010516767A/ja not_active Withdrawn
-
2009
- 2009-07-21 IL IL199992A patent/IL199992A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2676387A1 (en) | 2008-07-31 |
| EP2117556A2 (en) | 2009-11-18 |
| AU2008209555A1 (en) | 2008-07-31 |
| WO2008091620A3 (en) | 2008-09-18 |
| IL199992A0 (en) | 2010-04-15 |
| JP2010516767A (ja) | 2010-05-20 |
| WO2008091620A2 (en) | 2008-07-31 |
| US20090105200A1 (en) | 2009-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008091620A3 (en) | Combination therapy comprising romidepsin and i.a. bortezomib | |
| ZA202307538B (en) | Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis | |
| GB2430935A (en) | Tetrapeptide analogs | |
| SG164368A1 (en) | Treatment of cancer | |
| MX361467B (es) | Compuestos de isoindolina para uso en el tratamiento de cancer. | |
| PT1742644E (pt) | Composição terapêutica que contém pelo menos um derivado de pirrolobenzodiazepina e fludarabina | |
| MX2007002398A (es) | Nuevas composiciones farmaceuticas para el tratamiento de cancer. | |
| GB2420559B (en) | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses | |
| MX2007009649A (es) | Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer. | |
| IL184872A0 (en) | Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers | |
| IL185063A0 (en) | Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers | |
| MX2009006466A (es) | Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina. | |
| IN2012DN01964A (es) | ||
| SI1819227T1 (sl) | Farmacevtska formulacija decitabina | |
| MA32140B1 (fr) | Utilisation d'un anticorps anti-cd20 de type ii à cytotoxicité cellulaire accrue dépendant des anticorps (adcc) combiné au cyclophosphamide, à la vincristine et à la doxorubicine pour traiter les lymphomes non hodgkiniens | |
| EP4360712A3 (en) | Aryl- or heteroaryl-substituted benzene compounds | |
| BRPI0416981A (pt) | compostos para tratamento de doenças proliferativas de célula | |
| SG160412A1 (en) | Anti-igfr1 antibody therapeutic combinations | |
| GEP20115304B (en) | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα | |
| GEP20125469B (en) | Inhibitors of akt activity | |
| MX2007011545A (es) | Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr. | |
| WO2006020722A3 (en) | Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting | |
| AU2010266004A8 (en) | Method of treating cancer with Dll4 antagonist and chemotherapeutic agent | |
| PL1641803T6 (pl) | Pochodne tienopirymidyny jako inhibitory kanału potasowego | |
| TW200616615A (en) | Compounds and methods for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| FA | Abandonment or withdrawal |